Projects per year
Fingerprint
Dive into the research topics where Sandra Tuyaerts is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 3 Active
-
OZR3913: Cofinancing OZR FWO Hercules MZW - High-parametric single-cell protein profiling in intact tissues
Movahedi, K., van Grunsven, L., Rooman, I., Van Ginderachter, J., Smolders, I., Neyns, B., Vanhaecke, T., Laoui, D., Breckpot, K., De Veirman, K., Stijlemans, B., Van Schependom, J., Magez, S., Goyvaerts, C., De Kock, J., De Leu, N., Massie, A., Hellemans, K., Spits, C., De Bundel, D., De Trez, C., Hernot, S., Van Dooren, S., Aerts, J., Staels, W. & Tuyaerts, S.
25/02/22 → 25/02/26
Project: Fundamental
Research output
-
Current "state of the art" on dendritic cell-based cancer vaccines in melanoma
Schwarze, J. K., Geeraerts, X., Tuyaerts, S. & Neyns, B., 1 Mar 2023, In: Current Opinion in Oncology. 35, 2, p. 87-93 7 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study
De Jaeghere, E. A., Tuyaerts, S., Van Nuffel, A. M. T., Belmans, A., Bogaerts, K., Baiden-Amissah, R., Lippens, L., Vuylsteke, P., Henry, S., Trinh, X. B., van Dam, P. A., Aspeslagh, S., De Caluwé, A., Naert, E., Lambrechts, D., Hendrix, A., De Wever, O., Van de Vijver, K. K., Amant, F., Vandecasteele, K. & 1 others, , Feb 2023, In: Cancer Immunol Immunother. 72, 2, p. 475-491 17 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Citations (Scopus) -
790 Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab
Tijtgat, J., Schwarze, J. K., Vander Mijnsbrugge, A-S., Raeymaeckers, S., Van Riet, I., Geeraerts, X., Stevens, L., Tuyaerts, S. & Neyns, B., 7 Nov 2022, In: Journal for immunotherapy of cancer. 10, Suppl 2Research output: Contribution to journal › Meeting abstract (Journal)
Open Access -
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB)
Schwarze, J. K., Geens, W., Tijtgat, J., Awada, G., Seynaeve, L., Vanbinst, A-M., Everaert, H., Michotte, A., Bruneau, M., Van Riet, I., Tuyaerts, S., Duerinck, J. & Neyns, B., 1 Jun 2022, In: Journal of Clinical Oncology. 40, 16, 2033.Research output: Contribution to journal › Meeting abstract (Journal)
Open Access -
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB)
Schwarze, J. K., Geens, W., Tijtgat, J., Awada, G., Vanbinst, A., Everaert, H., Seynaeve, L., Michotte, A., Bruneau, M., VAN RIET, I., Tuyaerts, S., Duerinck, J. & Neyns, B., 3 Jun 2022.Research output: Unpublished contribution to conference › Poster
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 Mar 2022Activity: Talk or presentation › Talk or presentation at a conference
-
Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): a multi-cohort adaptive phase I clinical trial
Julia Katharina Schwarze (Speaker), Wietse Geens (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), Anne-Marie Van Binst (Contributor), Hendrik Everaert (Contributor), Laura Seynaeve (Contributor), Alex Michotte (Contributor), Michaël Bruneau (Contributor), I VAN RIET (Contributor), Sandra Tuyaerts (Contributor), Johnny Duerinck (Contributor) & Bart Neyns (Contributor)
16 Sep 2021 → 21 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
-
A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Presenter), Jens Tijtgat (Contributor), Gil Awada (Contributor), Louise Cras (Contributor), Inès Dufait (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor) & Bart Neyns (Contributor)
17 Sep 2021Activity: Talk or presentation › Talk or presentation at a conference
-
Human relevant models for drug research and development
Fien Meeus (Speaker), Robin Maximilian Awad (Contributor), Nick Devoogdt (Contributor), Sandra Tuyaerts (Contributor), Cleo Goyvaerts (Contributor), Yannick De Vlaeminck (Contributor), Bart Neyns (Contributor) & Karine Breckpot (Contributor)
8 Oct 2021Activity: Talk or presentation › Talk or presentation at a workshop/seminar